Rhythm Pharmaceuticals
Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

Biotechnology
WebsiteInvestor RelationsSEC
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

$6.3B

Market Cap • 10/9/2026

2008

(18 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

60,7

P/S

26,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,5

EPS

—

Market Cap

Market Cap

6,3B

EV

6B

EV/Revenue

25,2

EV/EBITDA

-30,3

EV/EBIT

-30,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3,2%

Total Yield

-3,2%

Payout

0%

Retained Earnings

-1,5B

Profitability

Gross Margin

89%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

72,2%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

278,5%

CAGR Op. Income 5Y

6,8%

CAGR Net Income 5Y

27,7%

CAGR EPS 5Y

18%

CAGR OCF 5Y

-2,8%

Leverage

N.D./EBITDA

1,6

Debt/Equity

0%

Current Ratio

3,5

Quick Ratio

3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium